I’d invest £500 in this FTSE 100 high-dividend-yield stock today 

I like it for its dividends and return on capital.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

One pound coin

Image source: Getty Images.

The FTSE 100 pharmaceuticals and consumer healthcare giant GlaxoSmithKline (LSE: GSK) saw a sharp fall in share price earlier in February. The price fell over 4% after the company released its 2019 results.

More than a week later, the price is still in free-fall. It was down 7.3% at the last close compared to the day before the results. It’s now at levels not seen since October. 

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

On the face of it, there’s little not to like about GSK’s results. 2019 was another year of increases in both revenue and earnings, and the company has also improved its cashflow for the second year straight.

So why the fall? And is this a buying opportunity or a sign of worse to come?

The future of dividends 

In a statement that has a direct bearing on investors’ income, GSK said “Expect 80p dividend for 2020”. This is in keeping with its dividend policy for the past few years.

At the present share price, this amounts to a dividend yield of 4.75% for the year (higher than the average for the FTSE 100). In other words, if I buy the GSK share today, my passive income from the share will be just shy of 5%.  

However, in the same breath the company has also said that the expected adjusted earnings per share (EPS) is likely to decline by 1%–4%, after increasing to 123.9p for 2019. A lower EPS increases the likelihood of a dividend cut since the company needs to earn enough to provide an income to its shareholders.

As far as this bit of guidance is concerned, I’m not worried, at least for now. Even if we assume a worst-case scenario, of a 4% decrease in EPS, the number is still at approximately 119p. With the dividend per share at 80p, the dividend cover is still a comfortable 1.5 times. 

Rising debts 

What I’m more concerned about is GSK’s rising debt level, which has increased by 16.6% over the past year. In relative terms, the number isn’t all that bad.

GSK’s debt-to-equity ratio, a measure of a company’s financial health, is at 2.5 times. This is higher than other pharmaceutical peers like AstraZeneca, whose ratio is less than 1.5 times. But in the context of GSK’s own past performance, it shows an improvement.

In 2018, GSK debt-to-equity ratio was almost 6 times. This means that in one year the ratio has actually more than halved, even if the absolute amount of debt has risen. I’d keep an eye out for the company’s debt numbers, but for now my concerns are muted.  

Healthy capital returns 

GSK has also given healthy returns to shareholders. In 2020 so far, its share price on average is 12.3% higher than in 2019, despite the latest decrease in share price. Besides this, it offers two other important advantages. One, it’s a defensive stock, which means it’s relatively insulated from cyclical slowdowns. Two, it offers a healthy dividend yield compared to other growth stocks 

In my view, the fall in price is a chance to buy a share that offers growth and dividends.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Manika Premsingh has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Should you invest the value of your investment may rise or fall and your Capital is at Risk. Before investing your individual circumstances should be considered, so you should consider taking independent financial advice.

More on Investing Articles

Portrait of construction engineers working on building site together
Investing Articles

Is this FTSE 100 stock the best housebuilder to invest in?

One FTSE 100 housebuilding stock has outperformed all of its industry peers by a big margin this year. Should I…

Read more »

pensive bearded business man sitting on chair looking out of the window
Investing Articles

2 cheap dividend growth stocks I’d buy as the economy sinks

I'm searching for the best bargains to buy following recent market volatility. Here are two top dividend growth stocks I…

Read more »

estate agent welcoming a couple to house viewing
Investing Articles

Here’s 1 FTSE stock primed to benefit from the current housing market!

With the current housing market as it is, Jabran Khan explores a related FTSE stock that could provide stable and…

Read more »

Portrait of construction engineers working on building site together
Investing Articles

Here’s why this AIM-listed stock could be one of the best shares to buy!

This Fool is looking for the best shares to buy. Despite macroeconomic issues, this stock could be a great long-term…

Read more »

Elderly father and adult son work in the garden
Investing Articles

This penny stock could be set to soar! Should I buy shares?

This Fool looks closely at a penny stock operating in an exciting growth market that could see its shares rise…

Read more »

Illustration of bull and bear
Investing Articles

The next stock market recovery looks imminent

As the stock market bear gives way to the bull, some stocks are already turning up and I'm ready to…

Read more »

Young mixed-race woman looking out of the window with a look of consternation on her face
Investing Articles

2 dividend shares to protect me from soaring inflation

Dividend shares can be an excellent way to keep up with inflation. Our writer explores several options to protect his…

Read more »

Middle-aged white man pulling an aggrieved face while looking at a screen
Investing Articles

Is it time to buy Unilever stock?

Unilever stock has underperformed in the last five years. But with its portfolio of powerful brands, should I buy now…

Read more »